December 15, 2017 / 11:16 AM / a month ago

BRIEF-Egalet Receives FDA Tentative Approval For Chronic Pain Treatment Drug

Dec 15 (Reuters) - Egalet Corp:

* EGALET RECEIVES FDA TENTATIVE APPROVAL FOR EXPANDED LABEL FOR ARYMO® ER (MORPHINE SULFATE) C-II, AN EXTENDED-RELEASE MORPHINE PRODUCT FORMULATED WITH ABUSE-DETERRENT PROPERTIES FOR TREATMENT OF CHRONIC PAIN

* EGALET - FINAL APPROVAL EXPECTED TO BE GRANTED WHEN EXCLUSIVITY PERIOD EXPIRES ON OCT. 2, 2018

* EGALET CORP - ‍INTRANASAL ABUSE-DETERRENT CLAIM TO BE ADDED TO ARYMO ER PRESCRIBING INFORMATION LABEL FOR ARYMO ER C-II​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below